Skip to main content
News > News > Jerome Hamilton Appointed CEO Of Open Therapeutics

Jerome Hamilton Appointed CEO Of Open Therapeutics

CINCINNATI, OH – Jerome Hamilton has been appointed CEO of Open Therapeutics LLC according to Founder & Executive Chair of the Board, Jason E. Barkeloo.

In the coming months Open TherapeuticsTM will provide a crowdsourcing web platform that will host freely available open pharma and medical technologies framework, created by Barkeloo and his team, to global researchers. Scientists can freely adopt the open technologies and develop manuscripts of the science they conduct around the technologies.

Hamilton will lead Open Therapeutics’ scale and global expansion, as well as manage business development, sales, marketing, and investor relations.

Hamilton joins Open Therapeutics after serving as Stratasys’ Senior Vice President of Global Operations, before which he was Vice President of LEAN Six Sigma Operations, Corporate Quality and Acquisition Integration for 3M. There, he played a major role in devising strategy and operational plans for the company’s largest business group, Industrial Business Group. He also led the company’s Masking and Surface Protection Business with full P&L responsibility.

“With the Open Therapeutics’ unique model, we will break down the pharma silos of non-disclosure that limit collaboration amongst scientists,” says Hamilton.

Hamilton received his Bachelor of General Science from Morehouse College, his Bachelor of Science for Industrial Engineering from Georgia Tech, Master of Science in Engineering Management from University of Detroit, Mercy; and Master of Science for International Logistics from Georgia Tech; he is a graduate of the Advanced Management Program, Harvard Business School.

Hamilton is a member of the Boards of Directors of Goodwill Easter Seals Minnesota, Real Life 101, and V2SOFT. He was listed in the 2014 Savoy Magazine list of Most Influential Blacks in Corporate America and was recognized as one of the Top 50 diversity professionals in industry– Global Diversity List, supported by The Economist, (

About Open TherapeuticsTM LLC

Open Therapeutics is a seven-year old company that curates and develops open medical, biopharma, and synthetic biology-based biotechnologies. Among the technologies being freely opened and crowdsourced to the global community are essential proteins for developing antibiotic and anticancer therapeutics, immunotherapy and oncolytics, and biomarker inducers. The Company is headquartered in Cincinnati, Ohio with laboratory operations in Covington, Kentucky, USA, and Madrid, Spain via its strategic partner, Bacmine SL, (

Read at

Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.